# MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

> **NCT00996801** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 526 (actual)

## Conditions studied

- Osteoporosis
- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** MK-5442
- **DRUG:** Placebo to MK-5442
- **DRUG:** Alendronate Sodium
- **DRUG:** Vitamin D3
- **DRUG:** Calcium carbonate
- **DRUG:** Placebo to Alendronate

## Key facts

- **NCT ID:** NCT00996801
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 526 (ACTUAL)
- **Last updated:** 2016-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996801, "MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00996801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*